Infliximab in the treatment of moderate to severe atopic dermatitis
- 1 March 2005
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 52 (3), 522-526
- https://doi.org/10.1016/j.jaad.2004.11.022
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Potential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic ArthritisArchives of Dermatology, 2004
- Infliximab for psoriasisJournal of the American Academy of Dermatology, 2003
- International Consensus Conference on Atopic Dermatitis II (ICCAD II*): clinical update and current treatment strategiesBritish Journal of Dermatology, 2003
- Atopic dermatitisThe Lancet, 2003
- Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitorsAnnals Of The Rheumatic Diseases, 2002
- Atopic dermatitis: New insights and opportunities for therapeutic interventionJournal of Allergy and Clinical Immunology, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Epidermal Cytokines IL-1β, TNF-α, and IL-12 in Patients with Atopic Dermatitis: Response to Application of House Dust Mite Antigens11This work is published in part as an abstract inArch Dermatol Res 1997, 289 (Suppl.): A45Journal of Investigative Dermatology, 1998
- Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in the epidermisArchiv für dermatologische Forschung, 1998